Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-caed-1_16-cv-00393/USCOURTS-caed-1_16-cv-00393-6/pdf.json

Nature of Suit Code: 367
Nature of Suit: TORTS - Personal Injury - Health Care/Pharmaceutical Personal Injury/Product Liability
Cause of Action: 28:1332 Diversity-Wrongful Death

---

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

1

UNITED STATES DISTRICT COURT

EASTERN DISTRICT OF CALIFORNIA

KRISTI LAURIS, et. al.,

Plaintiffs,

v.

NOVARTIS AG, et al.,

Defendants.

Case No. 1:16-cv-00393-LJO-SAB

ORDER ADOPTING FINDINGS AND 

RECOMMENDATIONS

(ECF Nos. 33-35, 44, 45, 48)

The complaint in this action was filed on March 22, 2016. On June 20, 2016, Defendant 

Novartis Pharmaceuticals Corporation (“NPC”) filed a motion to dismiss in which Defendant 

Novartis AG joined. The motion was referred to the undersigned for issuance of findings and 

recommendations pursuant to 28 U.S.C. § 636(b)(1)(B) and Local Rule 302. 

On March 14, 2014, the magistrate judge filed a findings and recommendations. The 

findings and recommendations recommended denying Defendants’ motion to dismiss. The 

findings and recommendations was served on the parties and contained notice that any objections 

to were to be filed within fourteen days (14) days from the date of service. The period for filing 

objections has passed and no objections have been filed. 

In accordance with the provisions of 28 U.S.C. § 636(b)(1)(C), this Court has conducted 

a de novo review of this case. Having carefully reviewed the entire file, the Court finds the 

findings and recommendations to be supported by the record and by proper analysis.

Case 1:16-cv-00393-SAB Document 51 Filed 08/09/16 Page 1 of 2
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

2

Accordingly, IT IS HEREBY ORDERED that:

1. The findings and recommendations, filed July 22, 2016, is ADOPTED IN FULL; 

and

2. Defendants Novartis Pharmaceutical Corporation and Novartis AG’s motion to 

dismiss is DENIED.

IT IS SO ORDERED.

Dated: August 9, 2016 /s/ Lawrence J. O’Neill _____ 

UNITED STATES CHIEF DISTRICT JUDGE

Case 1:16-cv-00393-SAB Document 51 Filed 08/09/16 Page 2 of 2